Abstract

To understand the prevalence of intrapartum oxytocin use, assess associated perinatal and maternal outcomes, and evaluate the impact of a WHO Safe Childbirth Checklist intervention on oxytocin use at primary-level facilities in Uttar Pradesh, India. Secondary analysis of a cluster-randomised controlled trial. Thirty Primary and Community public health facilities in Uttar Pradesh, India from 2014 to 2017. Women admitted to a study facility for childbirth at baseline, 2, 6 or 12 months after intervention initiation. The BetterBirth intervention aimed to increase adherence to the WHO Safe Childbirth Checklist. We used Rao-Scott Chi-square tests to compare (1) timing of oxytocin use between study arms and (2) perinatal mortality and resuscitation of infants whose mothers received intrapartum oxytocin versus who did not. Intrapartum and postpartum oxytocin administration, perinatal mortality, use of neonatal bag and mask. We observed 5484 deliveries. At baseline, intrapartum oxytocin was administered to 78.2% of women. Two months after intervention initiation, intrapartum oxytocin (I) was administered to 32.1% of women compared with 70.6% in the control (C) (P<0.01); this difference diminished after the end of the intervention (I=48.2%, C=74.7%, P=0.03). Partograph use remained at <1% at all facilities. Resuscitation was performed on 7.5% of infants whose mother received intrapartum oxytocin versus 2.0% who did not (P<0.0001). In this setting, intrapartum oxytocin use was high despite limited maternal/fetal monitoring or caesarean capability, and was associated with increased neonatal resuscitation. The BetterBirth intervention was successful at decreasing intrapartum oxytocin use. Ongoing support is needed to sustain these practices. Coaching+WHO Safe Childbirth Checklist reduces intrapartum oxytocin use and need for newborn resuscitation.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call